This is a biotech conference call (Morgan Stanley Biotech Without Borders) featuring Everest Medicines, not a Workday earnings call. The discussion centers on Everest's global partnership with Travere Therapeutics for its BTK inhibitor, its mRNA platform, and in vivo CAR-T development. Everest Medicines has closed a global partnership with Travere Therapeutics for sivipirbutinib (Ever001), targeting immune-mediated kidney diseases.
This is a biotech conference call (Morgan Stanley Biotech Without Borders) featuring Everest Medicines, not a Workday earnings call. The discussion centers on Everest's global partnership with Travere Therapeutics for its BTK inhibitor, its mRNA platform, and in vivo CAR-T development. Everest Medicines has closed a global partnership with Travere Therapeutics for sivipirbutinib (Ever001), targeting immune-mediated kidney diseases.
This is a biotech conference call (Morgan Stanley Biotech Without Borders) featuring Everest Medicines, not a Workday earnings call. The discussion centers on Everest's global partnership with Travere Therapeutics for its BTK inhibitor, its mRNA platform, and in vivo CAR-T…
Everest Medicines has closed a global partnership with Travere Therapeutics for sivipirbutinib (Ever001), targeting immune-mediated kidney diseases.
The partnership aims to leverage Travere's nephrology expertise for global development and commercialization outside Greater China and select APAC markets.
Everest's pipeline includes mRNA cancer vaccines (EVM-14, EVM-16) with a Phase 1b IIT study in first-line NSCLC maintenance expected to initiate in H2 2025.
The call focused on pipeline progress and partnership strategy rather than near-term financial guidance, with a tone of cautious optimism about upcoming data readouts and partnership interest.
Management expressed strong conviction in the partnership, pipeline differentiation, and progress across multiple programs.
Travere is the global commercialization and development partner for Everest's lead asset, and is credited with deep nephrology expertise and prior FDA approvals, strengthening its pipeline beyond its current assets.
“Trivier is a recognized leader in rare kidney disease. They have very established clinical development, regulatory, and commercial capabilities focused specifically on nephrology.”
Thank you, Jack, and welcome, Ian, and welcome, everyone, and thanks for dialling in. So, first question, Ian, on the partnership rationale and the operating model. So, with the Travere transaction now closed, what made Travere the right global partner for this asset, and how will the two companies divide development responsibilities, indication prioritisation, and decision-making from here?
Great. Thank you for the question. And, you know, it really is a pleasure to join this call and, you know, share our perspectives on the Ever001-Oseva-Ributnit collaboration with Travere. So, you know, so why do we think, you know, Travere is the right partner? I think, you know, first and foremost, we really believe Travere, there is a very strong strategic fit with Everest. Trivier is a recognized leader in rare kidney disease. They have very established clinical development, regulatory, and commercial capabilities focused specifically on nephrology. I think as part of our interactions and due diligence on Travere, we noticed that they have the number of people that they have 100% focused on nephrology is really not that different from on an FTE basis at a large pharma company. So we really feel comfortable with their specific expertise in this space. Obviously, also, they demonstrated with sparsantan or filspari, you know, how they were able to get this product through clinical development and the regulatory approval as the first ever FDA approved treatment for FSGS and the second FDA approved treatment for IgA nephropathy. We just have an enormous amount of confidence in their ability to both speed up and maximize the value of SIVO. So, you know, I think because of their expertise in nephrology, they really view the CVR bootnip not just as a PMN asset, but a potential pipeline in the product, right? You know, across multiple immune-mediated kidney diseases, you know, which is exactly how we think about this opportunity. So, you know, this transaction, I think, really creates a very complementary partnership, right? you know, Everest has generated the initial clinical approval concept in PMN and Trivia Brewing's extensive global nephrology expertise, very long-standing relationships with investigators and regulators, and an existing commercial infrastructure serving nephrologists. That's also exceedingly important. So combining those strengths, we believe, gives SIBO the best opportunity to become a global therapy. From a development perspective, Travere will lead the development and commercialization in the licensed territories. Those are outside of Greater China and a few APAC markets. We'll continue to work in our territories. We're already working closely on development strategy, clinical execution, and the regulatory interactions, and we will ensure …